Your trusted source for investing success

Tag: pipeline

Falco Announces Positive Feasibility Study Results on Horne 5 Gold Project

Falco Announces Positive Feasibility Study Results on Horne 5 Gold Project

-Top Quartile Project at All-In Sustaining Costs of US$399/oz Au, net of By-Product Credits
-All-In Cost (CAPEX plus OPEX) at US$643/oz Au
-Annual Payable Gold Production of 219,000 Ounces for 15 Years
-After-Tax IRR of 15.3%
Falco Resources Ltd. (“Falco” or the “Company”)(TSXV:FPC) is pleased to announce the results of a feasibility study (the “Feasibility Study”

ENPAR Technologies Inc. to Acquire Pumptronics Incorporated

ENPAR Technologies (TSXV:ENP) has announced it has entered into a binding letter of intent with Pumptronics to acquire 100 percent of the issue share capital for a transaction equal to $3 million, which is made up of $1.2 million in cash and 12 million common shares of ENPAR.

As quoted in

PacBio and Bluebee Launch De Novo Genome Assembly Pipeline on the Bluebee Analysis Platform

Bluebee, a company driving genomic data-driven medicine, and Pacific Biosciences of California, Inc. (NASDAQ: PACB), the leader in long-read sequencing, announced they have integrated the PacBio® de novo assembly pipeline onto the Bluebee® genomics analysis platform. The integration creates a simplified workflow and fully automated, end-to-end data analysis solution that allows

Valens Groworks Signs Craftgrow Deal With Canopy Growth

Valens Groworks Signs Craftgrow Deal With Canopy Growth

Valens GroWorks Corp. (CSE:VGW) (“Valens GroWorks”, or the “Company”) is pleased to announce that its wholly owned subsidiary Valens Agritech Ltd. (“Valens”), a Health Canada Licensed Dealer, has signed a supply and sales agreement with Canopy Growth Corporation (TSX: WEED) (“Canopy Growth”) for the distribution, marketing and sale of the

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA.  The poster entitled “Distinct mechanism of

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
Boralex and Infinergy Announce Joint Venture for 325 MW Onshore Wind in the UK

URL: https://investingnews.com/daily/tech-investing/cleantech-investing/boralex-infinergy-announce-joint-venture-325-mw-onshore-wind-uk/